Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3270-3274

  Cao, Shousong ^a,c   Black, Jennifer D ^a   Troutt, Anthony B ^b   Rustum, Yoncef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b AMGEN INC   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROTECTION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLON; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DUODENUM; FEMALE; INTERLEUKIN-15; INTESTINAL MUCOSA; PARAFFIN EMBEDDING; RATS; RATS, INBRED F344;

EID: 0032146257     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T-C., Sun, M., Pulliam, S., and Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 709-715, 1996.
2. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., Bonneterre, J., Adenis, A., Seitz, J. F., Ganem, G., Namer, M., Conroy, T., Negrier, S., Merrouche, Y., Burki, F., Mousseau, M., Herait, P., and Mahjoubi, M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol., 15: 251-260, 1997.
3. Cunningham, D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur. J. Cancer, 32A (Suppl. 3): S1-S8, 1996.
4. Shimada, Y., Rougier, P., and Pilot, H. Efficacy of CPT-11 (irinotecan) as a single agent in metastalic colorectal cancer. Eur. J. Cancer, 32A (Suppl. 3): S13-S17, 1996.
5. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
6. Von Hoff, D. Future directions for clinical research with CPT-11 (irinotecan). Eur. J. Cancer, 32A (Suppl. 3): S9-S12, 1996.
7. Abigerges, D., Armand, J. P., Chabot, G. G., Costa, L. D., Fadel, E., Cote, C., Herait, P., and Gandia, D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl. Cancer Inst. (Bethesda), 86: 446-449, 1994.
8. Goncalves, E., da Costa, L., Abigerges, D., and Armand, J. P. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J. Clin. Oncol., 13: 2144-2146, 1995.
9. Sakata, Y., Suzuki, H., and Kamataki, T. Preventive effect of TJ-14, a kampo medicine, on diarrhea induced by irinotecan. Proc. Am. Soc. Clin. Oncol., 13: 456, 1994.
10. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, K., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Giri, J. G. Clone of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science (Washington DC), 264: 965-968, 1994.
11. Cao, S., Troutt, A. B., and Rustum, Y. M. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res., 58: 1695-1699, 1998.
12. Reinecker, H-C., MacDermott, R. P., Mirau, S., Dignass, A., and Podolsky, D. K. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology, 111: 1706-1713, 1996.
13. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.
14. Takasuna, K., Kasai, Y., Kitano, Y., Mori, K., Kobayashi, R., Hagiwara, T., Kakihata, K., Hirohashi, M., Nomura, M., Nagai, N., and Kamataki, T. Protective effects of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 86: 978-984, 1995.
15. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702, 1993.
16. Ikuno, N., Soda, H., Watanabe, M., and Oka, M. Irinotecan (CPT-11) and characteristic mucosal change in the mouse ileum and cecum. J. Natl. Cancer Inst. (Bethesda), 87: 1876-1883, 1995.
17. Takasuna, K., Kasai, Y., Kitano, Y., Kakihata, K., Hirohashi, M., and Nomura, M. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol. Jpn., 105: 447-460, 1995.
18. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Namoru, M., Nagai, E., Yokoi, T., and Kamataki, T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 56: 3752-3757, 1996.
19. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
20. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.